Morgan Stanley has downgraded Inspire Medical Systems Inc (INSP) to Equal-Weight from Overweight as of December 1, 2025. The stock currently trades at $133.06.
This move underscores a shift in sentiment towards Inspire Medical Systems, which specializes in innovative, minimally invasive solutions for obstructive sleep apnea. The company's proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved, offering a safe treatment option for patients with moderate to severe cases of the condition.
With a market cap of $4.0 billion and a P/E ratio of 89.82, the company's recent earnings performance has shown significant surprises. For instance, in Q3 2025, Inspire reported an EPS of $0.34, well above the estimated loss of $0.20, marking a 271.7% surprise. Looking ahead, analysts anticipate earnings of $0.33 per share on revenue of $248.9 million for the upcoming earnings report on August 3, 2026.
Analyst ratings serve as one of many inputs for investment decisions, reflecting professional opinions based on research and financial models. As such, they can change over time with new information. Currently, the consensus rating for Inspire Medical Systems stands at Buy, with 6 Strong Buy, 13 Buy, and 7 Hold ratings among 26 analysts.
As the market evolves, it's crucial for investors to consider a range of factors, including company fundamentals and competitive positioning, rather than relying solely on analyst ratings.